2024
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology 2024, keae060. PMID: 38341669, DOI: 10.1093/rheumatology/keae060.Peer-Reviewed Original ResearchNail psoriasisJoint involvementPsoriatic arthritisJoint tendernessTargeting IL-17ADistal interphalangeal joint involvementPost hoc analysisPost-baseline assessmentSPIRIT-H2HInhibitor adalimumabIL-17AAdalimumabStudy cohortTNF-aDrug classesMusculoskeletal outcomesPsoriasisPatientsHoc analysisDistal interphalangealIxekizumabSynovio-entheseal complexWeeksAdjacent nailPSA
2022
Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
Strober B, Bukhalo M, Armstrong A, Pariser D, Kircik L, Parhami S, Montgomery P, Dickerson T. Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes. SKIN The Journal Of Cutaneous Medicine 2022, 6: 458-462. DOI: 10.25251/skin.6.6.2.Peer-Reviewed Original ResearchPhysician prescribing behaviorPatient outcomesPsoriasis patientsPrescribing behaviorClinical utilityExact testMatch StudyChoice of biologicsFisher's exact testPhysician decision makingBiologic selectionBiologic-naïveClinical outcomesLesional skinPsoriasis treatmentDrug classesPatient responsePatient managementWeek 4PatientsPhysician behaviorPhysiciansHealthcare systemBaselineInterim measurements
2017
Janus Kinase Inhibitors
Kim A, Strober B. Janus Kinase Inhibitors. 2017, 187-198. DOI: 10.1007/978-3-319-66884-0_19.Peer-Reviewed Original ResearchAutoinflammatory disordersJanus kinase inhibitorNovel drug classJanus kinaseMedication classesAtopic dermatitisRheumatoid arthritisAlopecia areataHematologic disordersClinical dataDrug classesPolycythemia veraTherapeutic benefitJAK inhibitorsNew agentsJAK-STAT pathwayClinical useJakinibsKinase inhibitorsActivator of transcriptionDisordersPreliminary findingsSignal transducerInhibitorsHuman use
2007
The use of therapeutic interchange for biologic therapies.
Flood J, Mihalik C, Fleming R, Strober B, Zucker D, Burgoyne D. The use of therapeutic interchange for biologic therapies. Managed Care 2007, 16: 51-62. PMID: 17285813.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsProton pump inhibitorsBiologic agentsTherapeutic interchangeRheumatoid arthritisBiologic therapyHMG-CoA reductase inhibitorsSerotonin reuptake inhibitorsPopulation-based outcomesHealth care professionalsMode of administrationOverall treatment costsTolerability profileAppropriate therapyReuptake inhibitorsPsoriasis therapyPump inhibitorsDrug classesIndividual patientsCare professionalsNew agentsEnzyme inhibitorsPatientsReductase inhibitorsTherapy